D3 receptor gene polymorphism and the results of Trial Making Testin patients with schizophrenia
Słowa kluczowe:
schizophrenia, polymorphism of dopamine receptorsAbstrakt
Cognitive deficits are a major problem in clinical psychiatry and their presence adversely affects the course of the disease and adaptation of schizophrenic patients. Intensity of these deficits in the groups of patients varies, and their origin and relation to brain structure abnormalities in schizophrenia is not fully understood. The authors studied 34 hospitalized patients with schizophrenia paranoid psychosis in its acute phase. They analyzed the relationship between some polymorphisms of histamine H1, serotonin, dopamine D2, D3 receptor genes and the results of Trail Making Test. It has been shown that patients with schizophrenia with Ser/Ser polymorphism of D3 receptor gene present lower levels of functioning in the visual-spatial operational memory and switching than those with Ser/Gly polymorphism of this gene.
Bibliografia
1. Arranz M.J., Murno J., Birkett J., Bolonna A., Sodhi M., Lesch K.P., Meyer J.F., Sham P., Collier D.A., Murray R.M., Kerwin R.W. Pharmacogenetic prediction of clozapine response. Lancet, 2000; 356: 1615-1616.
2. Ellingrod V.L., Perry P.J., Lund B.C., Bever-Stille K., Fleming F., Holman T.L., Miller D. 5HT2C and 5HT2A receptor polymorphism and Predicting response to olanzapine in schizophrenia. J. Clin. Psychopharmacol., 2002; 22: 622-624.
3. Godlewska B.R., Olajossy-Hilkesberger L., Ciwoniuk M., Olajossy M., Marmurowska-Michałowska H., Limon J, Landowski J. Olanzapine-induced weight gain is associated with the -759C/T and -697G/C polymorphisms of the HTR2C gene. Pharmacogenomics J., 2009; 4: 234-241.
4. Kolakowska T., Williams A.O., Arden M., Reverly M.A., Jambor K., Gedler M.G., Mandelbrot B.M. Schizophrenia with good and poor outcome.1. Early clinical features, response to neuroleptic and sings of organic dysfunction. Br. J. Psychiary, 1985: 146: 229-239.
5. Lan H.Y., Chang Y.C., Chiu C.C., Chen M.L., Hsih M.H., Chang W.H. Risperidone treatment of Assotiation response with polymorphism in the 5HT2A gene or prescriptions. Am. J. Psyhiatry, 2002; 1593-1595.
6. Lan H.Y., HSUS S., Liu Y., Chang Y., Huang C., Chang W. Dopamine D3 Ser/Gly polymorphism and Risperidone response. J. Clin. Psychopharmacol., 2005; 25: 6-11.
7. Olajossy-Hilkesberger L., Godlewska B., Olajossy M., Wojcierowski J., Landowski J., Marmurowska-Michałowska H., Kasper S., Polymorphism of the 5HT2A receptor gene and clinical response to olan fastened in paranoid schizophrenia /in press/.
8. Reynolds G.P., Yao Z., Zhang X., Sun J., Zhang Z. Pharmacogenetics of treatment in first episode schizophrenia; D3 receptor polymorphism and 5HT2C separately associate with positive and negative symptom response. European Neuropsychopharmacology, 2005; 15: 143-151.
9. Rybakowski J.K., Borkowska A., Czerski P.M., Dmitrzak-Weglarz M., Skibinska M., Kapelski P., Hauser J., Performance of the Wisconsin Card Sorting Test in schizophrenia and genes of dopaminergic inactivation /COMT, DAT, NET/. Psychiatry Res., 2006; 143:13-19.
10. Wexler B.E., Zhu H., Bell M.D., Nicholls S.S., Fulbright R.K., Gorge J.C., Colibazzi T., Amat J., Bansal R., Peterson B.S. Nu-
